JINHAI MED TECH (02225) climbed more than 5% in the afternoon session on Monday, bringing its cumulative gains since being added to the Stock Connect program to nearly 50%. As of the time of writing, the stock was up 5.79% at HK$6.21, with turnover reaching HK$11.36 million.

On the news front, the Shenzhen Stock Exchange announced on September 7 that, in accordance with the Shenzhen-Hong Kong Stock Connect implementation rules, the list of eligible securities for the southbound trading channel had been adjusted and took effect on the same day. Among the changes, JINHAI MED TECH has been included in the Stock Connect list. This inclusion is expected to broaden the company's shareholder base, attract long-term institutional investors, and enhance the liquidity of its shares.

Notably, in the first half of the year, JINHAI MED TECH saw a significant optimization in its revenue structure. Revenue from minimally invasive surgical solutions and medical products reached S$25.43 million, representing a staggering 301.5% year-on-year increase and accounting for 74.73% of total revenue, all of which came from the Chinese market. The financial report also revealed that the company accrued Chinese corporate income tax for the first time in the first half, indicating that its medical business in China has crossed the break-even point operationally.